Enterprise Value
-2.508M
Cash
51.89M
Avg Qtr Burn
-8.571M
Short % of Float
0.89%
Insider Ownership
33.23%
Institutional Own.
19.18%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CAN-2409 Details Prostate cancer, Cancer, Solid tumor/s | Phase 2 Data readout | |
CAN-2409 + Valacyclovir w/ PD-(L)1 targeting agents Details Lung cancer, Cancer, Solid tumor/s, Non-small cell lung carcinoma | Phase 2 Data readout | |
CAN-2409 + Valacyclovir w/ SoC Details Pancreatic cancer | Phase 2 Data readout | |
CAN-3110 Details Solid tumor/s, Cancer, Glioma | Phase 1 Data readout | |
CAN-2409 + Opdivo Details Cancer, Glioma, Solid tumor/s | Failed Discontinued |